In our study, we used Bcl-xs/l antibody that recognized a common motif of Bcl-xl and Bcl-xs, and primarily the motif in Bcl-xs. Our result suggested that expression of Bcl-xs/l was low in endometrial lesion tissue of high Bcl-xl expression, implying low expression of Bcl-xs in these tissues. In summary, our results suggested that abnormal elevation GS-1101 manufacturer of Bcl-xl expression and abnormal decrease of Bcl-xs expression played an important role in the development of endometrial carcinoma. When malignant biological behaviors of endometrial carcinoma
developded, Bcl-xs gene expression was significantly decreased, providing a new tumor marker for the early diagnosis of endometrial carcinoma. Further studies on the action mechanisms of Bcl-xl and Bcl-xs gene should provide new molecular targets for gene therapy of endometrial carcinoma. Acknowledgements This project was supported by funding from Liaoning Provincial Education Department and in collaboration with the Biochemical department and other relevant departments. Funding: Program of Shenyang Science and Technology Bureau(080671) References 1. Jemal A, Siegel R, Ward E: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43–66.PubMedCrossRef 2. Druilhe A, Arock M, Goffl Le: Human eosinophils express BCL-2 family proteins modulation of Mcl-1 expression by IFN-gamma. Am J Respir Cell Mol Biol 1998, 18:315.PubMed
3. Kawatani M, moto M: Deletion of the BH1 domain of Bcl-2 accelerates check details apoptosis by acting in a dominant negative fashion.
Cell Cycle inhibitor Biol Chem 2003, 278:19732–19742.CrossRef 4. Boise LH, Gonzalez-Garcia M, postema CE: Bcl-x, Sucrase a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:579–608.CrossRef 5. Sumantran VN, Ealovega MW, Nunez G: Over expression of Bcl-xs sensitives MCF-7 cells to chemotherapy induced apoptosis. Cancer Res 2005, 65:3507–3516. 6. Chauhan MA, Velankar M, Brahmandam M: A novel bcl-2/bcl-x(l)/bcl-w inhibitor ABT-737 as therapy in multipl myeloman. Oncogene 2006, 52:3102–3109. 7. Haynik DM, Prayson RA: Immunohistochemical Expression of bcl-2, bcl-x, and Bax in Follicular Carcinoma of the Thyroid. Appl Immunohistochem Mol Morphol 2006, 14:417–421.PubMedCrossRef 8. Boise LH, Thompson CB: Bcl-X(L) can inhibit apoptosis in cells that have under go Fasind- uces protease activation. Proc Natl Acad Sci USA 1997, 94:3759–3764.PubMedCrossRef 9. Lee DH, Szczepanski M, Lee YJ: Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. Biochem Pharmacol 2008, 75:2345–2355.PubMedCrossRef 10. Smythe WR, Mohuiddin I, Ozveran M: Antisense therapy for malignant mesothelioma with oligonucleotides targeting the Bcl-xl gene product. Thorac Cardiovasc Surg 2002, 123:1191–1198.CrossRef 11. Boehm A, Sen M, Seethala R: Combined Targeting of EGFR, STAT3, and Bcl-XL Enhances Antitumor Effects in Squamous Cell. Mol Pharmacol 2008, 69:3806–3816. 12.